title: Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda.
abstract: BACKGROUND
  Tuberculosis (TB) is the leading cause of death among people with HIV in sub-Saharan Africa. Expanding access to antiretroviral therapy (ART) may reduce the burden of TB, but to what extent is unknown.
  
  
  METHODS
  In a study of 1044 adults who initiated home-based ART in Tororo, Uganda between 1 May 2003 and 30 June 2005, participants were screened for active TB at baseline and then monitored at weekly home visits. Participants with TB at baseline or follow-up were compared with those without TB to determine factors associated with mortality in those with TB.
  
  
  RESULTS
  At baseline, 75 (7.2%) subjects had TB and a total of 53 (5.5%) were diagnosed with TB over a median of 1.4 years of follow-up (3.90 cases/100 person years). Cumulative mortality was 17.9/100 person-years for those with TB and 3.8/100 person-years for those without TB (P < 0.001). Mortality was associated with low baseline CD4 cell counts [relative hazard (RH), 0.99 per 1 cell/microl increase; P = 0.03] and marginally associated with a body mass index <or= 18 (RH, 2.04; P = 0.10) and increasing age (RH, 1.04 per year; P = 0.11). TB incidence and TB-associated mortality were highest within the first 6 months of ART and declined to 52% and 61% of expected values, respectively, from months 7 to 18 after ART initiation.
  
  
  CONCLUSIONS
  TB remains an important cause of illness and death in patients receiving ART in Uganda. However, both appear to decline markedly, after 6 months of ART.
authors.affiliation: Global AIDS Program, US Centers for Disease Control and Prevention (CDC), Entebbe, Uganda. dmoore@cfenet.ubc.ca
authors.forename: David
authors.initials: D
authors.lastname: Moore
authors.forename: Cheryl
authors.initials: C
authors.lastname: Liechty
authors.forename: Paul
authors.initials: P
authors.lastname: Ekwaru
authors.forename: Willy
authors.initials: W
authors.lastname: Were
authors.forename: Gerald
authors.initials: G
authors.lastname: Mwima
authors.forename: Peter
authors.initials: P
authors.lastname: Solberg
authors.forename: George
authors.initials: G
authors.lastname: Rutherford
authors.forename: Jonathan
authors.initials: J
authors.lastname: Mermin
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality; D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D015995:Prevalence; D012307:Risk Factors; D012423:Rural Health; D014376:Tuberculosis / Q000453:epidemiology* / Q000401:mortality; D014397:Tuberculosis, Pulmonary / Q000453:epidemiology / Q000401:mortality; D014454:Uganda / Q000453:epidemiology
chemical_list: D044966:Anti-Retroviral Agents